At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNTM Quantum Biopharma Ltd.
Not Yet Opened 09-08 16:00:00 EDT
3.29
+0.05
+1.54%
盘后3.38
+0.09+2.85%
19:56 EDT
High3.37Low3.06Vol131.19K
Open3.28D1 Closing3.24Amplitude9.57%
Mkt Cap26.61MTradable Cap25.17MTotal Shares8.09M
T/O426.27KT/O Rate1.71%Tradable Shares7.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quantum Biopharma Amends Form 6-K to Add Exhibit to F-3 Registration Statement
Reuters  ·  00:39
Quantum Biopharma Amends Form 6-K to Add Exhibit to F-3 Registration Statement
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
TIPRANKS  ·  09-01
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
Quantum Biopharma Provides Corporate Update
GlobeNewswire  ·  08-22
Quantum Biopharma Provides Corporate Update
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
TIPRANKS  ·  08-20
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Dow Jones  ·  08-14
Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
TIPRANKS  ·  08-13
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
Quantum Biopharma Ltd Expected to Post a Loss of 42 Cents a Share - Earnings Preview
Reuters  ·  08-12
Quantum Biopharma Ltd Expected to Post a Loss of 42 Cents a Share - Earnings Preview
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
TIPRANKS  ·  08-11
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
GlobeNewswire  ·  08-10
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results
TIPRANKS  ·  08-04
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results
Quantum Biopharma Ltd Expected to Post a Loss of 42 Cents a Share - Earnings Preview
Reuters  ·  08-01
Quantum Biopharma Ltd Expected to Post a Loss of 42 Cents a Share - Earnings Preview
Quantum BioPharma Announces Closing of Debt Settlement
GlobeNewswire  ·  07-30
Quantum BioPharma Announces Closing of Debt Settlement
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
TIPRANKS  ·  07-29
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
Press Release: Quantum Biopharma Announces Intention to Settle Debt
Dow Jones  ·  07-21
Press Release: Quantum Biopharma Announces Intention to Settle Debt
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
TIPRANKS  ·  07-16
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
TIPRANKS  ·  07-11
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Quantum BioPharma Provides Corporate Update
GlobeNewswire  ·  07-08
Quantum BioPharma Provides Corporate Update
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast
TIPRANKS  ·  07-02
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
TIPRANKS  ·  06-30
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
GlobeNewswire  ·  06-25
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Introduction

Company Name.
Quantum Biopharma Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
Issue price:
--